Surufatinib

Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.

It is also under investigation for the treatment of other types of solid tumors.

Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).